company background image
CTE

CryositeASX:CTE Stock Report

Market Cap

AU$17.1m

7D

-5.4%

1Y

45.8%

Updated

15 Oct, 2021

Data

Company Financials
CTE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends0/6

CTE Overview

Cryosite Limited provides outsourced clinical trials logistic services in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Cryosite
Historical stock prices
Current Share PriceAU$0.35
52 Week HighAU$0.16
52 Week LowAU$0.47
Beta0.41
1 Month Change-13.58%
3 Month Change-12.50%
1 Year Change45.83%
3 Year Changen/a
5 Year Change79.49%
Change since IPO-20.45%

Recent News & Updates

Shareholder Returns

CTEAU Life SciencesAU Market
7D-5.4%-0.1%0.1%
1Y45.8%-3.4%19.3%

Return vs Industry: CTE exceeded the Australian Life Sciences industry which returned -3.4% over the past year.

Return vs Market: CTE exceeded the Australian Market which returned 19.3% over the past year.

Price Volatility

Is CTE's price volatile compared to industry and market?
CTE volatility
CTE Beta0.41
Industry Beta0.95
Market Beta1

Stable Share Price: CTE is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CTE's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199920John Hogghttps://www.cryosite.com

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport solutions, and biological storage services to the clinical trial and research industry.

Cryosite Fundamentals Summary

How do Cryosite's earnings and revenue compare to its market cap?
CTE fundamental statistics
Market CapAU$17.08m
Earnings (TTM)AU$652.57k
Revenue (TTM)AU$10.02m

26.2x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CTE income statement (TTM)
RevenueAU$10.02m
Cost of RevenueAU$4.13m
Gross ProfitAU$5.89m
ExpensesAU$5.24m
EarningsAU$652.57k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.013
Gross Margin58.80%
Net Profit Margin6.51%
Debt/Equity Ratio0%

How did CTE perform over the long term?

See historical performance and comparison

Valuation

Is Cryosite undervalued compared to its fair value and its price relative to the market?

26.2x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CTE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CTE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CTE is good value based on its PE Ratio (26.2x) compared to the Global Life Sciences industry average (46x).

PE vs Market: CTE is poor value based on its PE Ratio (26.2x) compared to the Australian market (19.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CTE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CTE is overvalued based on its PB Ratio (45.3x) compared to the AU Life Sciences industry average (4.9x).


Future Growth

How is Cryosite forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

41.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cryosite has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Cryosite performed over the past 5 years?

35.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CTE has high quality earnings.

Growing Profit Margin: CTE's current net profit margins (6.5%) are lower than last year (16.6%).


Past Earnings Growth Analysis

Earnings Trend: CTE's earnings have grown significantly by 35.4% per year over the past 5 years.

Accelerating Growth: CTE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CTE had negative earnings growth (-55.9%) over the past year, making it difficult to compare to the Life Sciences industry average (59.8%).


Return on Equity

High ROE: CTE's Return on Equity (172.8%) is considered outstanding.


Financial Health

How is Cryosite's financial position?


Financial Position Analysis

Short Term Liabilities: CTE's short term assets (A$7.3M) exceed its short term liabilities (A$3.5M).

Long Term Liabilities: CTE's short term assets (A$7.3M) do not cover its long term liabilities (A$18.1M).


Debt to Equity History and Analysis

Debt Level: CTE is debt free.

Reducing Debt: CTE has not had any debt for past 5 years.

Debt Coverage: CTE has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CTE has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Cryosite current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CTE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CTE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: CTE is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTE's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average board tenure


CEO

John Hogg

1

Tenure

AU$336,745

Compensation

Mr. John Hogg has been Chief Executive Officer at Cryosite Limited since October 15, 2020. Mr. Hogg joined Cryosite in July 2018 and was promoted to General Manager of Operations on the 1st December 2019....


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD249.72K) is about average for companies of similar size in the Australian market ($USD300.24K).

Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.


Board Members

Experienced Board: CTE's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.2%.


Top Shareholders

Company Information

Cryosite Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Cryosite Limited
  • Ticker: CTE
  • Exchange: ASX
  • Founded: 1999
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$17.083m
  • Shares outstanding: 48.81m
  • Website: https://www.cryosite.com

Number of Employees


Location

  • Cryosite Limited
  • 13a Ferndell Street
  • South Granville
  • New South Wales
  • 2142
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/15 07:02
End of Day Share Price2021/10/12 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.